{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:47:52Z","timestamp":1780879672254,"version":"3.54.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mast cells can reshape the tumour immune microenvironment and greatly affect tumour occurrence and development. However, mast cell gene prognostic and predictive value in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study was conducted to identify and establish a prognostic mast cell gene signature (MCS) for assessing the prognosis and immunotherapy response of patients with HNSCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Mast cell marker genes in HNSCC were identified using single-cell RNA sequencing analysis. A dataset from The Cancer Genome Atlas was divided into a training cohort to construct the MCS model and a testing cohort to validate the model. Fluorescence in-situ hybridisation was used to evaluate the MCS model gene expression in tissue sections from patients with HNSCC who had been treated with programmed cell death-1 inhibitors and further validate the MCS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A prognostic MCS comprising nine genes (<jats:italic>KIT<\/jats:italic>, <jats:italic>RAB32<\/jats:italic>, <jats:italic>CATSPER1<\/jats:italic>, <jats:italic>SMYD3<\/jats:italic>, <jats:italic>LINC00996<\/jats:italic>, <jats:italic>SOCS1<\/jats:italic>, <jats:italic>AP2M1<\/jats:italic>, <jats:italic>LAT<\/jats:italic>, and <jats:italic>HSP90B1<\/jats:italic>) was generated by comprehensively analysing clinical features and 47 mast cell-related genes. The MCS effectively distinguished survival outcomes across the training, testing, and entire cohorts as an independent prognostic factor. Furthermore, we identified patients with favourable immune cell infiltration status and immunotherapy responses. Fluorescence in-situ hybridisation supported the MCS immunotherapy response of patients with HNSCC prediction, showing increased high-risk gene expression and reduced low-risk gene expression in immunotherapy-insensitive patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our MCS provides insight into the roles of mast cells in HNSCC prognosis and may have applications as an immunotherapy response predictive indicator in patients with HNSCC and a reference for immunotherapy decision-making.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09673-3","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T06:05:11Z","timestamp":1653372311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Mast cell marker gene signature in head and neck squamous cell carcinoma"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhimou","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9720-1997","authenticated-orcid":false,"given":"Wenbin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"issue":"1","key":"9673_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.canlet.2015.07.039","volume":"368","author":"L Hui","year":"2015","unstructured":"Hui L, Chen Y. Tumour microenvironment: Sanctuary of the devil. Cancer Lett. 2015;368(1):7\u201313.","journal-title":"Cancer Lett"},{"issue":"18","key":"9673_CR2","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/0008-5472.CAN-18-3962","volume":"79","author":"DC Hinshaw","year":"2019","unstructured":"Hinshaw DC, Shevde LA. The Tumour Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019;79(18):4557\u201366.","journal-title":"Cancer Res"},{"issue":"11","key":"9673_CR3","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. NAT REV IMMUNOL. 2015;15(11):669\u201382.","journal-title":"NAT REV IMMUNOL"},{"issue":"1","key":"9673_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bbadis.2010.11.010","volume":"1822","author":"D Ribatti","year":"2012","unstructured":"Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochim Biophys Acta. 2012;1822(1):2\u20138.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"9673_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12016-019-08753-w","volume":"58","author":"D Komi","year":"2020","unstructured":"Komi D, Redegeld FA. Role of Mast Cells in Shaping the Tumour Microenvironment. Clin Rev Allergy Immunol. 2020;58(3):313\u201325.","journal-title":"Clin Rev Allergy Immunol"},{"key":"9673_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-030-49270-0_9","volume":"1273","author":"A Aponte-Lopez","year":"2020","unstructured":"Aponte-Lopez A, Munoz-Cruz S. Mast Cells in the Tumour Microenvironment. Adv Exp Med Biol. 2020;1273:159\u201373.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"9673_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"9673_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"9673_CR9","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal Heterogeneity and Tumour Evolution: Past, Present, and the Future. CELL. 2017;168(4):613\u201328.","journal-title":"CELL"},{"issue":"17","key":"9673_CR10","doi-asserted-by":"publisher","first-page":"e89829","DOI":"10.1172\/jci.insight.89829","volume":"1","author":"R Mandal","year":"2016","unstructured":"Mandal R, Senbabaoglu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 2016;1(17):e89829.","journal-title":"JCI Insight"},{"issue":"2","key":"9673_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tranon.2019.11.008","volume":"13","author":"F Perri","year":"2020","unstructured":"Perri F, Ionna F, Longo F, Della VSG, De Angelis C, Ottaiano A, et al. Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy. Transl Oncol. 2020;13(2):262\u201374.","journal-title":"Transl Oncol"},{"issue":"19","key":"9673_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856\u201367.","journal-title":"N Engl J Med"},{"issue":"14","key":"9673_CR13","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","volume":"35","author":"J Bauml","year":"2017","unstructured":"Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J CLIN ONCOL. 2017;35(14):1542\u20139.","journal-title":"J CLIN ONCOL"},{"key":"9673_CR14","doi-asserted-by":"publisher","first-page":"614291","DOI":"10.1155\/2014\/614291","volume":"2014","author":"A Anuradha","year":"2014","unstructured":"Anuradha A, Kiran KNB, Vijay SG, Devi RS, Puneet HK. Incidence of mast cells in oral squamous cell carcinoma: a short study. J ONCOL. 2014;2014:614291.","journal-title":"J ONCOL"},{"issue":"10","key":"9673_CR15","doi-asserted-by":"publisher","first-page":"5499","DOI":"10.21873\/anticanres.11131","volume":"36","author":"CG Attramadal","year":"2016","unstructured":"Attramadal CG, Kumar S, Gao J, Boysen ME, Halstensen TS, Bryne M. Low Mast Cell Density Predicts Poor Prognosis in Oral Squamous Cell Carcinoma and Reduces Survival in Head and Neck Squamous Cell Carcinoma. Anticancer Res. 2016;36(10):5499\u2013506.","journal-title":"Anticancer Res"},{"issue":"4","key":"9673_CR16","first-page":"1227","volume":"52","author":"R Ciurea","year":"2011","unstructured":"Ciurea R, Margaritescu C, Simionescu C, Stepan A, Ciurea M. VEGF and his R1 and R2 receptors expression in mast cells of oral squamous cells carcinomas and their involvement in tumoural angiogenesis. Romanian J Morphol Embryol. 2011;52(4):1227\u201332.","journal-title":"Romanian J Morphol Embryol"},{"issue":"1","key":"9673_CR17","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1002\/cpmb.57","volume":"122","author":"TK Olsen","year":"2018","unstructured":"Olsen TK, Baryawno N. Introduction to Single-Cell RNA Sequencing. Curr Protoc Mol Biol. 2018;122(1):e57.","journal-title":"Curr Protoc Mol Biol"},{"key":"9673_CR18","doi-asserted-by":"crossref","unstructured":"Wolfien M, David R, Galow AM: Single-Cell RNA Sequencing Procedures and Data Analysis. 2021.","DOI":"10.36255\/exonpublications.bioinformatics.2021.ch2"},{"issue":"1","key":"9673_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","volume":"52","author":"AR Cillo","year":"2020","unstructured":"Cillo AR, Kurten C, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer. IMMUNITY. 2020;52(1):183\u201399.","journal-title":"IMMUNITY"},{"issue":"5","key":"9673_CR20","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol. 2018;36(5):411\u201320.","journal-title":"Nat Biotechnol"},{"key":"9673_CR21","doi-asserted-by":"crossref","unstructured":"Lall S, Sinha D, Bandyopadhyay S, Sengupta D. Structure-Aware Principal Component Analysis for Single-Cell RNA-seq Data. J Comput Biol. 2018.","DOI":"10.1089\/cmb.2018.0027"},{"issue":"5","key":"9673_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","volume":"33","author":"R Satija","year":"2015","unstructured":"Satija R, Farrell JA, Gennert D, Schier AF, Regev A. Spatial reconstruction of single-cell gene expression data. Nat Biotechnol. 2015;33(5):495\u2013502.","journal-title":"Nat Biotechnol"},{"issue":"D1","key":"9673_CR23","doi-asserted-by":"publisher","first-page":"D721","DOI":"10.1093\/nar\/gky900","volume":"47","author":"X Zhang","year":"2019","unstructured":"Zhang X, Lan Y, Xu J, Quan F, Zhao E, Deng C, et al. CellMarker: a manually curated resource of cell markers in human and mouse. Nucleic Acids Res. 2019;47(D1):D721\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"9673_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20(2):163\u201372.","journal-title":"Nat Immunol"},{"issue":"4","key":"9673_CR25","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3","volume":"16","author":"R Tibshirani","year":"1997","unstructured":"Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997;16(4):385\u201395.","journal-title":"Stat Med"},{"issue":"1","key":"9673_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"43","key":"9673_CR27","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-2","key":"9673_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","volume":"160","author":"MS Rooney","year":"2015","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumours associated with local immune cytolytic activity. CELL. 2015;160(1-2):48\u201361.","journal-title":"CELL"},{"issue":"1","key":"9673_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362.","journal-title":"Cell Rep"},{"issue":"3","key":"9673_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218.","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"9673_CR31","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","volume":"6","author":"JA Trujillo","year":"2018","unstructured":"Trujillo JA, Sweis RF, Bao R, Luke JJ. T Cell-Inflamed versus Non-T Cell-Inflamed Tumours: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. CANCER IMMUNOL RES. 2018;6(9):990\u20131000.","journal-title":"CANCER IMMUNOL RES"},{"key":"9673_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold Tumours: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168.","journal-title":"Front Immunol"},{"issue":"9","key":"9673_CR33","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/annonc\/mdw226","volume":"27","author":"P Economopoulou","year":"2016","unstructured":"Economopoulou P, Agelaki S, Perisanidis C, Giotakis EI, Psyrri A. The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 2016;27(9):1675\u201385.","journal-title":"Ann Oncol"},{"issue":"10","key":"9673_CR34","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41419-018-1100-1","volume":"9","author":"YP Lv","year":"2018","unstructured":"Lv YP, Peng LS, Wang QH, Chen N, Teng YS, Wang TT, et al. Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progression. Cell Death Dis. 2018;9(10):1034.","journal-title":"Cell Death Dis"},{"issue":"1","key":"9673_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40425-019-0530-3","volume":"7","author":"Y Lv","year":"2019","unstructured":"Lv Y, Zhao Y, Wang X, Chen N, Mao F, Teng Y, et al. Increased intratumoural mast cells foster immune suppression and gastric cancer progression through TNF-alpha-PD-L1 pathway. J IMMUNOTHER CANCER. 2019;7(1):54.","journal-title":"J IMMUNOTHER CANCER"},{"issue":"3","key":"9673_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.4103\/0973-1482.163693","volume":"14","author":"A Kabiraj","year":"2018","unstructured":"Kabiraj A, Jaiswal R, Singh A, Gupta J, Singh A, Samadi FM. Immunohistochemical evaluation of tumour angiogenesis and the role of mast cells in oral squamous cell carcinoma. J Cancer Res Ther. 2018;14(3):495\u2013502.","journal-title":"J Cancer Res Ther"},{"key":"9673_CR37","first-page":"424","volume":"8","author":"G Varricchi","year":"2017","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Marone G, Iannone R, Marone G, et al. Are Mast Cells MASTers in Cancer? Front Immunol. 2017;8:424.","journal-title":"Front Immunol"},{"issue":"7","key":"9673_CR38","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/j.1440-1746.2007.05009.x","volume":"24","author":"M Gulubova","year":"2009","unstructured":"Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009;24(7):1265\u201375.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"9673_CR39","first-page":"113","volume":"54","author":"GV Micu","year":"2016","unstructured":"Micu GV, Staniceanu F, Sticlaru LC, Popp CG, Bastian AE, Gramada E, et al. Correlations Between the Density of Tryptase Positive Mast Cells (DMCT) and that of New Blood Vessels (CD105+) in Patients with Gastric Cancer. Rom J Intern Med. 2016;54(2):113\u201320.","journal-title":"Rom J Intern Med"},{"issue":"4","key":"9673_CR40","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.surg.2010.10.009","volume":"149","author":"SW Cai","year":"2011","unstructured":"Cai SW, Yang SZ, Gao J, Pan K, Chen JY, Wang YL, et al. Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. SURGERY. 2011;149(4):576\u201384.","journal-title":"SURGERY"},{"key":"9673_CR41","doi-asserted-by":"crossref","unstructured":"Kaesler S, Wolbing F, Kempf WE, Skabytska Y, Koberle M, Volz T, et al. Targeting tumour-resident mast cells for effective anti-melanoma immune responses. JCI. Insight. 2019;4(19).","DOI":"10.1172\/jci.insight.125057"},{"issue":"4","key":"9673_CR42","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1083\/jcb.200204081","volume":"158","author":"NM Alto","year":"2002","unstructured":"Alto NM, Soderling J, Scott JD. Rab32 is an A-kinase anchoring protein and participates in mitochondrial dynamics. J Cell Biol. 2002;158(4):659\u201368.","journal-title":"J Cell Biol"},{"key":"9673_CR43","doi-asserted-by":"crossref","unstructured":"Drizyte-Miller K, Chen J, Cao H, Schott MB, McNiven MA. The small GTPase Rab32 resides on lysosomes to regulate mTORC1 signaling. J Cell Sci. 2020;133(11).","DOI":"10.1242\/jcs.236661"},{"issue":"4","key":"9673_CR44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5230\/jgc.2017.17.e33","volume":"17","author":"L Wang","year":"2017","unstructured":"Wang L, Wang QT, Liu YP, Dong QQ, Hu HJ, Miao Z, et al. ATM Signaling Pathway Is Implicated in the SMYD3-mediated Proliferation and Migration of Gastric Cancer Cells. J GASTRIC CANCER. 2017;17(4):295\u2013305.","journal-title":"J GASTRIC CANCER"},{"issue":"1","key":"9673_CR45","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.canlet.2009.02.015","volume":"280","author":"JN Zou","year":"2009","unstructured":"Zou JN, Wang SZ, Yang JS, Luo XG, Xie JH, Xi T. Knockdown of SMYD3 by RNA interference down-regulates c-Met expression and inhibits cells migration and invasion induced by HGF. Cancer Lett. 2009;280(1):78\u201385.","journal-title":"Cancer Lett"},{"issue":"3","key":"9673_CR46","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1093\/nar\/gky1221","volume":"47","author":"C Fenizia","year":"2019","unstructured":"Fenizia C, Bottino C, Corbetta S, Fittipaldi R, Floris P, Gaudenzi G, et al. SMYD3 promotes the epithelial-mesenchymal transition in breast cancer. Nucleic Acids Res. 2019;47(3):1278\u201393.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"9673_CR47","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1093\/nar\/gkx1259","volume":"46","author":"XD Zhang","year":"2018","unstructured":"Zhang XD, Huang GW, Xie YH, He JZ, Guo JC, Xu XE, et al. The interaction of lncRNA EZR-AS1 with SMYD3 maintains overexpression of EZR in ESCC cells. Nucleic Acids Res. 2018;46(4):1793\u2013809.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"9673_CR48","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.18632\/aging.102718","volume":"12","author":"G Wang","year":"2020","unstructured":"Wang G, Huang Y, Yang F, Tian X, Wang K, Liu L, et al. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R\/AKT\/E2F-1 positive feedback loop in bladder cancer. Aging (Albany NY). 2020;12(3):2030\u201348.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"9673_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13148-021-01021-9","volume":"13","author":"BJ Bernard","year":"2021","unstructured":"Bernard BJ, Nigam N, Burkitt K, Saloura V. SMYD3: a regulator of epigenetic and signaling pathways in cancer. Clin Epigenetics. 2021;13(1):45.","journal-title":"Clin Epigenetics"},{"issue":"8","key":"9673_CR50","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1111\/odi.13506","volume":"26","author":"CC Wu","year":"2020","unstructured":"Wu CC, Li H, Xiao Y, Deng WW, Sun ZJ. Expression levels of SIX1, ME2, and AP2M1 in adenoid cystic carcinoma and mucoepidermoid carcinoma. Oral Dis. 2020;26(8):1687\u201395.","journal-title":"Oral Dis"},{"issue":"3","key":"9673_CR51","doi-asserted-by":"publisher","first-page":"4140","DOI":"10.1002\/jcb.27699","volume":"120","author":"SH Cho","year":"2019","unstructured":"Cho SH, Pak K, Jeong DC, Han ME, Oh SO, Kim YH. The AP2M1 gene expression is a promising biomarker for predicting survival of patients with hepatocellular carcinoma. J Cell Biochem. 2019;120(3):4140\u20136.","journal-title":"J Cell Biochem"},{"issue":"10","key":"9673_CR52","doi-asserted-by":"publisher","first-page":"14321","DOI":"10.1007\/s13277-016-5304-7","volume":"37","author":"Y Xu","year":"2016","unstructured":"Xu Y, Chen Z, Zhang G, Xi Y, Sun R, Wang X, et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumour Biol. 2016;37(10):14321\u20138.","journal-title":"Tumour Biol"},{"key":"9673_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12885-015-1212-2","volume":"15","author":"AE Rodriguez-Vicente","year":"2015","unstructured":"Rodriguez-Vicente AE, Quwaider D, Benito R, Misiewicz-Krzeminska I, Hernandez-Sanchez M, de Coca AG, et al. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer. 2015;15:238.","journal-title":"BMC Cancer"},{"issue":"23","key":"9673_CR54","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1080\/15384101.2019.1673633","volume":"18","author":"C Fang","year":"2019","unstructured":"Fang C, Xu L, He W, Dai J, Sun F. Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis. Cell Cycle. 2019;18(23):3288\u201399.","journal-title":"Cell Cycle"},{"issue":"3","key":"9673_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7150\/ijms.10735","volume":"12","author":"Z Yang","year":"2015","unstructured":"Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12(3):256\u201363.","journal-title":"Int J Med Sci"},{"issue":"26","key":"9673_CR56","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1038\/onc.2016.519","volume":"36","author":"Y Obata","year":"2017","unstructured":"Obata Y, Horikawa K, Takahashi T, Akieda Y, Tsujimoto M, Fletcher JA, et al. Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumours. ONCOGENE. 2017;36(26):3661\u201372.","journal-title":"ONCOGENE"},{"issue":"4","key":"9673_CR57","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","volume":"92","author":"J Lennartsson","year":"2012","unstructured":"Lennartsson J, Ronnstrand L. Stem cell factor receptor\/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619\u201349.","journal-title":"Physiol Rev"},{"issue":"4","key":"9673_CR58","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH818>3.0.CO;2-E","volume":"193","author":"S Hirota","year":"2001","unstructured":"Hirota S, Nishida T, Isozaki K, Taniguchi M, Nakamura J, Okazaki T, et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol. 2001;193(4):505\u201310.","journal-title":"J Pathol"},{"key":"9673_CR59","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.2147\/OTT.S173225","volume":"11","author":"H Ge","year":"2018","unstructured":"Ge H, Yan Y, Wu D, Huang Y, Tian F. Potential role of LINC00996 in colorectal cancer: a study based on data mining and bioinformatics. Onco Targets Ther. 2018;11:4845\u201355.","journal-title":"Onco Targets Ther"},{"issue":"6127","key":"9673_CR60","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LJ, Kinzler KW. Cancer genome landscapes. SCIENCE. 2013;339(6127):1546\u201358.","journal-title":"SCIENCE"},{"issue":"1","key":"9673_CR61","first-page":"29","volume":"28","author":"H Yoshikawa","year":"2001","unstructured":"Yoshikawa H, Matsubara K, Qian GS, Jackson P, Groopman JD, Manning JE, et al. SOCS-1, a negative regulator of the JAK\/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet. 2001;28(1):29\u201335.","journal-title":"Nat Genet"},{"issue":"6","key":"9673_CR62","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ijc.20521","volume":"112","author":"Y Oshimo","year":"2004","unstructured":"Oshimo Y, Kuraoka K, Nakayama H, Kitadai Y, Yoshida K, Chayama K, et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer. 2004;112(6):1003\u20139.","journal-title":"Int J Cancer"},{"issue":"5","key":"9673_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1755-148X.2008.00484.x","volume":"21","author":"S Liu","year":"2008","unstructured":"Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res. 2008;21(5):545\u201358.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"9673_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s100380300008","volume":"48","author":"H Nagai","year":"2003","unstructured":"Nagai H, Naka T, Terada Y, Komazaki T, Yabe A, Jin E, et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK\/STAT inhibitor, in human hepatoblastomas. J Hum Genet. 2003;48(2):65\u20139.","journal-title":"J Hum Genet"},{"issue":"1","key":"9673_CR65","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000450576","volume":"9","author":"L Portales-Cervantes","year":"2017","unstructured":"Portales-Cervantes L, Haidl ID, Lee PW, Marshall JS. Virus-Infected Human Mast Cells Enhance Natural Killer Cell Functions. J INNATE IMMUN. 2017;9(1):94\u2013108.","journal-title":"J INNATE IMMUN"},{"key":"9673_CR66","doi-asserted-by":"publisher","first-page":"718499","DOI":"10.3389\/fimmu.2021.718499","volume":"12","author":"AM Palma","year":"2021","unstructured":"Palma AM, Hanes MR, Marshall JS. Mast Cell Modulation of B Cell Responses: An Under-Appreciated Partnership in Host Defence. Front Immunol. 2021;12:718499.","journal-title":"Front Immunol"},{"issue":"9","key":"9673_CR67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. NAT REV IMMUNOL. 2017;17(9):559\u201372.","journal-title":"NAT REV IMMUNOL"},{"issue":"10167","key":"9673_CR68","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"E Cohen","year":"2019","unstructured":"Cohen E, Soulieres D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. LANCET. 2019;393(10167):156\u201367.","journal-title":"LANCET"},{"issue":"7","key":"9673_CR69","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","volume":"17","author":"TY Seiwert","year":"2016","unstructured":"Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. LANCET ONCOL. 2016;17(7):956\u201365.","journal-title":"LANCET ONCOL"},{"issue":"10","key":"9673_CR70","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","volume":"65","author":"MJ Duffy","year":"2019","unstructured":"Duffy MJ, Crown J. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. Clin Chem. 2019;65(10):1228\u201338.","journal-title":"Clin Chem"},{"issue":"3","key":"9673_CR71","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"key":"9673_CR72","first-page":"10","volume":"2019","author":"B Niu","year":"1888","unstructured":"Niu B, Zhou F, Su Y, Wang L, Xu Y, Yi Z, et al. Different Expression Characteristics of LAG3 and PD-1 in Sepsis and Their Synergistic Effect on T Cell Exhaustion: A New Strategy for Immune Checkpoint Blockade. Front Immunol. 1888;2019:10.","journal-title":"Front Immunol"},{"issue":"2","key":"9673_CR73","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.oooo.2017.05.474","volume":"124","author":"AM Bates","year":"2017","unstructured":"Bates AM, Lanzel EA, Qian F, Abbasi T, Vali S, Brogden KA. Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017;124(2):157\u201364.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"5","key":"9673_CR74","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/jmedgenet-2018-105610","volume":"57","author":"H Helgadottir","year":"2020","unstructured":"Helgadottir H, Ghiorzo P, van Doorn R, Puig S, Levin M, Kefford R, et al. Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline CDKN2A mutations. J Med Genet. 2020;57(5):316\u201321.","journal-title":"J Med Genet"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09673-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09673-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T07:03:41Z","timestamp":1653375821000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09673-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9673"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09673-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"assertion":[{"value":"19 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study designs and test procedures were performed in accordance with the Helsinki Declaration II. The study was approved by the ethics board of IEC for Clinical Research and Animal Trials of the First Affiliated Hospital of Sun Yat-sen University (approval no. [2020]220-1). All patients in this study provided informed consent and agreed to follow up after treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"577"}}